ExploreWatchlistsPricing
  1. JP-listed companies
  2. HEALIOS K.K.
  3. Financials
  4. Return on Assets

HEALIOS K.K. (4593)

Market cap
¥45B
P/E ratio
Helios develops stem cell treatments for hard-to-treat diseases using both somatic stem cells and iPS cells to create regenerative medicines.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndReturn on Assets (Million JPY)YoY (%)
Dec 31, 2025-14.2-50.83%
Dec 31, 2024-28.9+13.94%
Dec 31, 2023-25.3-4.42%
Dec 31, 2022-26.5+27.22%
Dec 31, 2021-20.8-7.87%
Dec 31, 2020-22.6+15.89%
Dec 31, 2019-19.5-24.76%
Dec 31, 2018-25.9+110.64%
Dec 31, 2017-12.3-64.75%
Dec 31, 2016-34.9+148.90%
Dec 31, 2015-14

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat